Indivior PLC (INDV) Stock Forecast & Price Target

Indivior PLC has demonstrated strong growth in its Sublocade treatment, with the number of patients increasing to approximately 171,500 in Q3 2025, reflecting an 8% year-over-year increase. The company has improved its revenue guidance for Sublocade to a range of $765 million to $786 million for 2025, attributed to ongoing volume growth, particularly within the Medicaid and commercial patient segments. Additionally, Indivior's leadership position in the medication-assisted treatment market positions it favorably to capitalize on the rising adoption rates of these therapies, driven by increased public awareness and reduced stigma surrounding addiction treatment.

Indivior PLC is expected to face significant revenue challenges as Suboxone continues to experience declines due to increasing generic competition, which jeopardizes the stability of the company's income stream. While there is optimism surrounding Sublocade's potential growth, it is currently early in its commercial lifecycle, suggesting that it may not yet be capable of fully offsetting the declines from Suboxone. Additionally, projected SG&A expenses are anticipated to remain high at approximately 45% of revenue in 2026, indicating a potential strain on profitability moving forward.